BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elan Corporation PLC (ELN) Not Impressed With Royalty Pharma's $6.5 Billion Takeover Bid


2/27/2013 7:48:42 AM

The board of Ireland-based drugmaker Elan Corp (NYSE: ELN) has acknowledged the takeover approach from private equity firm Royalty Pharma regarding an indicative, conditional, proposal which may or may not lead to an offer being made for the entire issued share capital of the company. The response came late the same day the offer of $11 per share of Elan was made, valuing the company at around $6.55 billion (The Pharma Letter February 25). The news saw Elan’s share price rise 6.4% to $11.28 in New York trading and up 6.9% to 8.52 euros in Dublin.Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here. As previously announced, in anticipation of executing and closing the recently-announced Tysabri (natalizumab) transaction (giving up rights to the multiple sclerosis drug in exchange for a $3.25 billion from partner Biogen Idec; TPL February 7 and 22), the Elan board, executive management and advisors have been working for over a year on a number of strategic transactions that, should they be consummated, would be to the benefit of our public shareholders.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES